Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS.

J Magn Reson Imaging. 2013 Nov;38(5):1043-53. doi: 10.1002/jmri.24079. Epub 2013 Mar 21.

PMID:
23908122
2.

Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.

Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O.

Mol Oncol. 2012 Aug;6(4):418-27. doi: 10.1016/j.molonc.2012.03.006. Epub 2012 Mar 31.

3.

Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.

Pöschinger T, Renner A, Eisa F, Dobosz M, Strobel S, Weber TG, Brauweiler R, Kalender WA, Scheuer W.

Invest Radiol. 2014 Jul;49(7):445-56. doi: 10.1097/RLI.0000000000000038.

PMID:
24598441
4.

Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.

Hahn SY, Ko EY, Han BK, Shin JH, Ko ES.

Eur J Radiol. 2014 Feb;83(2):283-8. doi: 10.1016/j.ejrad.2013.10.023. Epub 2013 Nov 20.

PMID:
24315957
5.

Use of diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MR imaging in the assessment of response to radiotherapy of lytic bone metastases from breast cancer.

Gaeta M, Benedetto C, Minutoli F, D'Angelo T, Amato E, Mazziotti S, Racchiusa S, Mormina E, Blandino A, Pergolizzi S.

Acad Radiol. 2014 Oct;21(10):1286-93. doi: 10.1016/j.acra.2014.05.021. Epub 2014 Aug 1.

PMID:
25088834
6.

Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.

Bäuerle T, Bartling S, Berger M, Schmitt-Gräff A, Hilbig H, Kauczor HU, Delorme S, Kiessling F.

Eur J Radiol. 2010 Feb;73(2):280-7. doi: 10.1016/j.ejrad.2008.10.020. Epub 2008 Dec 12.

PMID:
19070445
7.

Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.

Gaustad JV, Simonsen TG, Smistad R, Wegner CS, Andersen LM, Rofstad EK.

BMC Cancer. 2015 Nov 14;15:900. doi: 10.1186/s12885-015-1918-1.

8.

Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.

Jensen LR, Garzon B, Heldahl MG, Bathen TF, Lundgren S, Gribbestad IS.

J Magn Reson Imaging. 2011 Nov;34(5):1099-109. doi: 10.1002/jmri.22726. Epub 2011 Aug 23.

PMID:
22002757
9.

Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.

Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, Kitagaki H, Igawa M.

Acta Radiol. 2008 Dec;49(10):1207-13. doi: 10.1080/02841850802508959.

PMID:
19031184
10.

In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.

Huuse EM, Moestue SA, Lindholm EM, Bathen TF, Nalwoga H, Krüger K, Bofin A, Maelandsmo GM, Akslen LA, Engebraaten O, Gribbestad IS.

J Magn Reson Imaging. 2012 May;35(5):1098-107. doi: 10.1002/jmri.23507. Epub 2011 Dec 14.

PMID:
22170753
11.

Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.

Jeon TY, Kim CK, Kim JH, Im GH, Park BK, Lee JH.

Br J Radiol. 2015 Sep;88(1053):20150163. doi: 10.1259/bjr.20150163. Epub 2015 Jul 2.

12.

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM.

Magn Reson Imaging. 2007 Apr;25(3):319-27. Epub 2007 Feb 5.

PMID:
17371720
13.

Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.

Chen YF, Yuan A, Cho KH, Lu YC, Kuo MY, Chen JH, Chang YC.

PLoS One. 2017 Nov 9;12(11):e0187824. doi: 10.1371/journal.pone.0187824. eCollection 2017.

14.

Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin.

Chang YC, Yu CJ, Chen CM, Hu FC, Hsu HH, Tseng WY, Ting-Fang Shih T, Yang PC, Chih-Hsin Yang J.

J Magn Reson Imaging. 2012 Aug;36(2):387-96. doi: 10.1002/jmri.23660. Epub 2012 Apr 19.

PMID:
22517425
15.

Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.

Cyran CC, Fu Y, Rogut V, Chaopathomkul B, Wendland MF, Shames DM, Brasch RC.

Acad Radiol. 2013 Oct;20(10):1256-63. doi: 10.1016/j.acra.2013.07.010.

16.

Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ.

Neoplasia. 2005 May;7(5):475-85.

17.
18.

Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.

Song KD, Choi D, Lee JH, Im GH, Yang J, Kim JH, Lee WJ.

AJR Am J Roentgenol. 2014 Jun;202(6):W559-66. doi: 10.2214/AJR.13.11042.

PMID:
24848850
19.

Contribution of diffusion-weighted imaging to dynamic contrast-enhanced MRI in the characterization of breast tumors.

Kul S, Cansu A, Alhan E, Dinc H, Gunes G, Reis A.

AJR Am J Roentgenol. 2011 Jan;196(1):210-7. doi: 10.2214/AJR.10.4258.

PMID:
21178069
20.

Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI.

Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, Li LZ, Zhou R, Delikatny EJ, Poptani H, Glickson JD.

NMR Biomed. 2008 Nov;21(10):1021-9. doi: 10.1002/nbm.1261.

PMID:
18988250

Supplemental Content

Support Center